Cytotoxic and Apoptotic Effects of Pinostilbene and Bortezomib Combination Treatment on Human Multiple Myeloma Cells

被引:2
|
作者
Staskiewicz, Anna [1 ]
Wong, Erica [1 ]
Tucker, Michael [1 ]
Farhin, Riya [1 ]
Park, Jonathan [1 ]
Saade, Rana [1 ]
Alkhazali, Tina [1 ]
Dang, Tu [1 ]
Wang, Xinyu [1 ]
机构
[1] Philadelphia Coll Osteopath Med Georgia Campus, Coll Pharm, Dept Pharmaceut Sci, Suwanee, GA 30024 USA
关键词
multiple myeloma; bortezomib; resveratrol; pinostilbene; piceatannol; synergism; cytotoxicity; apoptosis; bone marrow microenvironment; oxidative stress; RESVERATROL INDUCES APOPTOSIS; OXIDATIVE STRESS; SENSITIVITY; SURVIVAL; PATHOGENESIS; INHIBITION; ACTIVATION; CASPASES; THERAPY; PHASE-2;
D O I
10.3390/ijms241612590
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow characterized by bone lesions, hypercalcemia, anemia, and renal failure. Bortezomib (BTZ), a common treatment for MM, is a proteasome inhibitor that induces apoptosis in MM cells. However, high doses of BTZ can be very toxic, signifying a need for a synergistic drug combination to improve treatment efficacy. Resveratrol (RES), a phenolic compound found in grapes, has been shown to inhibit MM cell growth. We sought to identify a synergistic combination of BTZ with a RES derivative and analyze the effects on reducing viability and inducing apoptosis in human MM cells. BTZ as well as RES and its derivatives pinostilbene (PIN) and piceatannol (PIC) decreased MM cell viability in a doseand time-dependent manner and increased expression of cleaved proapoptotic proteins poly(ADPribose) polymerase 1 (PARP1) and caspase-3 in a dose-dependent manner. The combination of 5 nM BTZ and 5 mu M PIN was identified to have synergistic cytotoxic effects in MM RPMI 8226 cells. MM RPMI 8226 cells treated with this combination for 24 h showed increased cleaved PARP1 and caspase-3 expression and higher percentages of apoptotic cells versus cells treated with the individual compounds alone. The treatment also showed increased apoptosis induction in MM RPMI 8226 cells co-cultured with human bone marrow stromal HS-5 cells in a Transwell model used to mimic the bone marrow microenvironment. Expression of oxidative stress defense proteins (catalase, thioredoxin, and superoxide dismutase) in RPMI 8226 cells were reduced after 24 h treatment, and cytotoxic effects of the treatment were ameliorated by antioxidant N-acetylcysteine (NAC), suggesting the treatment impacts antioxidant levels in RPMI 8226 cells. Our results suggest that this combination of BTZ and PIN decreases MM cell viability synergistically by inducing apoptosis and oxidative stress in MM cells.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] Synergistic Apoptotic Effects of Bortezomib and Methylstat on Multiple Myeloma Cells
    Kaci, Fatma Necmiye
    Kiraz, Yagmur
    Cekdemir, Demet
    Baran, Yusuf
    [J]. ARCHIVES OF MEDICAL RESEARCH, 2020, 51 (03) : 187 - 193
  • [2] BORTEZOMIB IN COMBINATION WITH CYTOTOXIC AGENT THERAPY FOR MULTIPLE MYELOMA
    Takamatsu, Y.
    Sunami, K.
    Miyamoto, T.
    Hata, H.
    Muta, T.
    Tsukada, J.
    Uozumi, K.
    Tamura, K.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 83 - 83
  • [3] CURCUMIN AND BORTEZOMIB HAVE SYNERGISTIC CYTOTOXIC EFFECTS AGAINST MULTIPLE MYELOMA CELLS
    Yosifov, D. Y.
    Guenova, M.
    Konstantinov, S. M.
    Berger, M. R.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 33 - 33
  • [4] Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells
    Song, In-Sung
    Jeong, Yu Jeong
    Jeong, Seung Hun
    Heo, Hye Jin
    Kim, Hyoung Kyu
    Lee, Sung Ryul
    Ko, Tae Hee
    Youm, Jae Boum
    Kim, Nari
    Ko, Kyung Soo
    Rhee, Byoung Doo
    Han, Jin
    [J]. EXPERIMENTAL AND MOLECULAR MEDICINE, 2013, 45 : e50 - e50
  • [5] Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells
    In-Sung Song
    Yu Jeong Jeong
    Seung Hun Jeong
    Hye Jin Heo
    Hyoung Kyu Kim
    Sung Ryul Lee
    Tae Hee Ko
    Jae Boum Youm
    Nari Kim
    Kyung Soo Ko
    Byoung Doo Rhee
    Jin Han
    [J]. Experimental & Molecular Medicine, 2013, 45 : e50 - e50
  • [6] Evaluation of potential cytotoxic and apoptotic effects of bioymifi on human multiple myeloma cell lines
    Terzi, Hatice
    Ergul, Merve
    [J]. TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2020, 19 (11) : 2363 - 2367
  • [7] Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma
    Manochakian, Rarni
    Miller, Kena C.
    Chanan-Khan, Asher Alban
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (04): : 266 - 271
  • [8] Effects of Arsenic Trioxide Alone and in Combination with Bortezomib in Multiple Myeloma RPMI 8266 Cells
    Elmahi, Aadil Yousif
    Niu, Chao
    Li, Wei
    Li, Dan
    Wang, Guan-Jun
    Hao, Shan-Shan
    Cui, Jiu-Wei
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (11) : 6469 - 6473
  • [9] Bortezomib Combination Therapy in Multiple Myeloma
    Kapoor, Prashant
    Ramakrishnan, Vijay
    Rajkumar, S. Vincent
    [J]. SEMINARS IN HEMATOLOGY, 2012, 49 (03) : 228 - 242
  • [10] Synergistic effects of curcumin and bortezomib on multiple myeloma cells
    Zheng, Cuiping
    Fan, Yufang
    Wu, Shenghao
    Cai, Xiaoping
    Shi, Yuejian
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (11): : 21787 - 21793